Grant Support

Current Grant Support

MACC Fund, “Targeted Molecular Radiotherapy to Improve the Outcomes in Children with Malignant Brain Tumors” (2017-2019). Otto, Principal Investigator

MACC Fund, “Strategies for Improving Recovery of Immune Function following TCRab-depleted Hematopoietic Stem Cell Transplantation” (2017-2019). Otto, Principal Investigator

Cannonball Kids’ Cancer Foundation, "TCR-alpha/beta+ and CD19+ depleted KIR/KIR ligand-mismatched haploidentical hematopoietic stem cell transplant and Zoledronate for pediatric relapsed/refractory hematologic malignancies and high risk solid tumors" (2016-2019). Otto, PI

UW Office of the Vice Chancellor for Research and Graduate Education and the UW Carbone Cancer Center, "Combining radiotherapeutic with antitumor antibody and IL2 to create a potent in situ cancer vaccine" (2016-2018). Otto, Co-PI

American Association of Immunologists (K. Kloepping fellowship), "A novel phospholipid ether analog to combine targeted molecular radiotherapy and immunotherapy in pediatric solid tumors," (2016-2017). Otto, Mentor

Hyundai Hope on Wheels, "A novel phospholipid ether analog to combine targeted molecular radiotherapy and immunotherapy in pediatric solid tumors” (2015-2018). Otto, PI

NIH/NCI (R21 CA198392), “A cancer-targeted phospholipid ether analog for molecular radiotherapy of pediatric solid tumors” (2015-2017).  Otto, PI

NIH/NCI & University of Wisconsin Carbone Cancer Center (P30 CA014520), “TCR-α/β+ and CD19+ depleted KIR/KIR ligand-mismatched haploidentical hematopoietic stem cell transplant and Zoledronate for pediatric relapsed/refractory hematologic malignancies and high risk solid tumors” (2016-2017).  Otto, Pilot Grant PI

Midwest Athletes Against Childhood Cancer, “Effect of Zoledronate on engraftment and t-cell development after TCR alpha-ß/CD19-depleted hematopoietic stem cell transplantation” (2015-2017).  Otto, PI

Midwest Athletes Against Childhood Cancer, “Clr1404 - A tumor-selective alkyl phospholipid analog for the treatment of pediatric solid malignancies” (2015-2017).  Otto, PI

AACR-St. Baldrick’s-SU2C Foundations “Immunogenomics to create new therapies for high-risk childhood cancers” (2013-2017).  Otto, Young Investigator

 


Completed Grants

 

Midwest Athletes Against Childhood Cancer, “Alpha/beta t-cell depleted haploidentical transplantation with post-transplant zoledronic acid to treat recurrent or refractory pediatric malignancies” (2013-2016).  Otto, Co-Investigator

Midwest Athletes Against Childhood Cancer, “Development of multifunctional superparamagnetic anti-GD2 nanoparticles for simultaneous molecular imaging, cancer cell targeting and drug delivery” (2011-2015).  Otto, PI

Alex’s Lemonade Stand Foundation for Childhood Cancer, “Development of an innovative treatment strategy for neuroblastoma and other pediatric tumors: a novel phospholipid ether analogue and its multifunctional cancer-targeting nanoconstruct” (2012-2014).  Otto, PI